SHENZHEN, China, Aug. 18,
2024 /PRNewswire/ -- Fapon Biotech is a global
leader in the In-vitro Diagnostics (IVD) industry,
with a steadfast commitment to advancing global health by providing
innovative diagnostic solutions. As the World Health
Organization (WHO) declared monkeypox outbreak as a public health
emergency of international concern (PHEIC) on Aug 14, Fapon Biotech
reaffirms its commitment by providing antigen diagnostic products
addressing this emerging threat.
![(PRNewsfoto/Fapon) (PRNewsfoto/Fapon)](https://mma.prnewswire.com/media/2472549/Fapon_Logo.jpg)
Since the outbreak of monkeypox in 2022, Fapon Biotech has been
continuously developing and upgrading its raw materials solutions
for monkeypox antigen rapid tests. Fapon's products for monkeypox
detection have high sensitivity, high specificity, and demonstrate
no cross-reactivity with non-OPXVs such as the varicella-zoster
virus. Fapon Biotech's solutions are developed to offer more
effective and accessible testing options, particularly for low- and
middle-income countries and regions, thereby facilitating rapid
diagnosis in such areas.
In 2023, the increased global circulation of the monkeypox virus
heightened the demand for diagnostics, altogether demonstrating a
clear need for simplified, automated, and accessible assay that are
available outside laboratories. In response, to enhance access to
quality-assured, accurate, and accessible monkeypox diagnostics,
WHO specified a target product profile designed for
decentralized use, including in community settings.
This measure has encouraged more IVD companies to develop POCT
products, that are more convenient and accessible for screening and
diagnosis in rural environments and areas with limited healthcare
resources.
In the ongoing battle against the spread of monkeypox, Fapon
Biotech stands committed to leveraging its expertise to fight this
global public health issue and assist its global partners in the
development of monkeypox diagnostic rapid tests. To explore how
Fapon Biotech can assist or collaborate, please email us at
market@fapon.com
With over 20 years of experience, Fapon Biotech has played a
pivotal role in developing IVD solutions to prevent the spread of
infectious disease agents such as HIV, hepatitis C, syphilis,
malaria, dengue, and respiratory diseases.
Looking into the future, our extensive expertise in antibody
design and cutting-edge technology, enables us to support the
development of diagnostic tests that provide earlier detection and
institution of treatment for the improvement of public health.
About Fapon Biotech
As a global leading in vitro
diagnostics (IVD) enterprise, Fapon Biotech Inc. (referred to as
"Fapon Biotech") focuses on the future needs and trends of
biotechnology development and is committed to providing global
partners with high-performance IVD reagent raw materials, reagent
services and innovative open instrument platforms.
Fapon Biotech aims to enable the development of the diagnostics
industry with our global partners, to achieve the mission of
"Delivering earlier, more accurate, convenient and accessible
diagnostics for everyone".
Follow us on LinkedIn (Fapon) or visit our website
https://en.faponbiotech.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fapon-biotech-delivers-antigen-diagnostic-solutions-to-help-control-monkeypox-outbreak-in-africa-302224816.html
SOURCE Fapon Biotech Inc.